General Information of Drug (ID: DM25QKC)

Drug Name
MK-1308 Drug Info
Synonyms Quavonlimab
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DM25QKC

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ipilimumab DMJTIYK Melanoma 2C30 Approved [3]
Tremelimumab DMOQ9H1 Hepatocellular carcinoma 2C12.02 Approved [4]
KN046 DMSDBPG Non-small-cell lung cancer 2C25.Y Phase 3 [5]
AK04 DMU7K86 Actinic keratosis EK90.0 Phase 3 [6]
AK104 DMXJ8Z4 Cervical cancer 2C77.0 Phase 2 [7]
Lorigerlimab DM2E8Z5 Prostate cancer 2C82.0 Phase 2 [8]
Vudalimab DMSEEI0 Prostate cancer 2C82.0 Phase 2 [9]
AGEN1884 DMAP5B4 Cervical cancer 2C77.0 Phase 1/2 [10]
BMS-986288 DMM10J4 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [11]
Zalifrelimab DMNNYAE Cervical cancer 2C77.0 Phase 1/2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4) TTI2S1D CTLA4_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT03179436) Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001). U.S. National Institutes of Health.
2 Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021 Mar;32(3):395-403.
3 Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2743).
5 Clinical pipeline report, company report or official report of Alphamab Oncology.
6 A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study). Lung Cancer. 2023 Oct;184:107355.
7 Clinical pipeline report, company report or official report of Akeso Biopharma.
8 Clinical pipeline report, company report or official report of MacroGenics
9 Clinical pipeline report, company report or official report of Xencor
10 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
11 Clinical pipeline report, company report or official report of CytomX Therapeutics.
12 Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. J Clin Oncol. 2022 Mar 1;40(7):762-771.